CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.

Abstract

Using a panel of seven brain cell-specific biomarkers in cerebrospinal fluid (CSF), pediatric opsoclonus-myoclonus syndrome (OMS) (n=234) was compared to pediatric non-inflammatory neurological controls (n=84) and other inflammatory neurological disorders (OIND) (n=44). Only CSF NFL was elevated in untreated OMS versus controls (+83%). It was 87% higher in OIND than in OMS. On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels. These biochemical data suggest neuronal/axonal injury in some children with OMS without indicators of astrogliosis, and reduction on sufficient immunotherapy.

• Authors: Michael R Pranzatelli, Elizabeth D Tate, Nathan R McGee, Steven J Verhulst
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 266 Issue 1-2 Pg. 75-81 (Jan 15 2014) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 24342231 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Cytokines
• Immunoglobulins, Intravenous
• Immunologic Factors
• Neurofilament Proteins
• neurofilament protein L
• Rituximab
• Adrenocorticotropic Hormone

Topics

• Adolescent
• Adrenocorticotropic Hormone (therapeutic use)
• Adult
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Child
• Child, Preschool
• Cross-Sectional Studies
• Cytokines (metabolism)
• Encephalitis (cerebrospinal fluid)
• Female
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Factors (therapeutic use)
• Male
• Neurofilament Proteins (cerebrospinal fluid)
• Observation
• Opsoclonus-Myoclonus Syndrome (cerebrospinal fluid)
• Retrospective Studies
• Rituximab
• Severity of Illness Index
• Young Adult